Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martyn J Burke

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
The Lancet. Oncology|March 31, 2015
NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomibMartyn J Burke, Elisabeth George, Amanda I Adler
International Journal of Pediatric Otorhinolaryngology|December 2, 2011
The economics of screening infants at risk of hearing impairment: an international analysisMartyn J Burke, Ruth C Shenton, Matthew J Taylor
The Lancet. Oncology|April 3, 2018
NICE guidance on everolimus in combination with exemestane for treatment of advanced HER2-negative, hormone-receptor-positive breast cancer after endocrine therapyMartyn J Burke, Zoe Garrett, Elisabeth George, et al.
The Lancet. Neurology|August 29, 2017
Dimethyl fumarate for relapsing-remitting multiple sclerosisMartyn J Burke, Joanna Richardson, Elisabeth George, et al.
The Lancet. Neurology|October 7, 2014
Alemtuzumab for relapsing-remitting multiple sclerosisRichard A Diaz, Sally Doss, Martyn J Burke, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
The Lancet. Oncology|March 31, 2015
NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomibMartyn J Burke, Elisabeth George, Amanda I Adler
International Journal of Pediatric Otorhinolaryngology|December 2, 2011
The economics of screening infants at risk of hearing impairment: an international analysisMartyn J Burke, Ruth C Shenton, Matthew J Taylor
The Lancet. Oncology|April 3, 2018
NICE guidance on everolimus in combination with exemestane for treatment of advanced HER2-negative, hormone-receptor-positive breast cancer after endocrine therapyMartyn J Burke, Zoe Garrett, Elisabeth George, et al.
The Lancet. Neurology|August 29, 2017
Dimethyl fumarate for relapsing-remitting multiple sclerosisMartyn J Burke, Joanna Richardson, Elisabeth George, et al.
The Lancet. Neurology|October 7, 2014
Alemtuzumab for relapsing-remitting multiple sclerosisRichard A Diaz, Sally Doss, Martyn J Burke, et al.
Pageof 1